ÀÚµ¿·Î±×¾Æ¿ô¾È³»
ÀÚµ¿ ·Î±×¾Æ¿ô ³²Àº ½Ã°£ : 30ÃÊ
°í°´´ÔÀÇ ¾ÈÀüÇÑ Á¤º¸º¸¾ÈÀ» À§ÇØ ·Î±×ÀÎ ÈÄ ¾à10ºÐµ¿¾È ¼ºñ½º ÀÌ¿ëÀÌ ¾ø¾î ÀÚµ¿ ·Î±×¾Æ¿ô µË´Ï´Ù. ·Î±×ÀÎ ½Ã°£À» ¿¬ÀåÇϽðڽÀ´Ï±î?
ÀÚµ¿·Î±×¾Æ¿ô¾È³»
°í°´´ÔÀÇ ¾ÈÀüÇÑ Á¤º¸º¸¾ÈÀ» À§ÇØ ·Î±×ÀÎ ÈÄ ¾à10ºÐµ¿¾È ¼ºñ½º ÀÌ¿ëÀÌ ¾ø¾î ÀÚµ¿ ·Î±×¾Æ¿ô µÇ¾ú½À´Ï´Ù.
Á¦22ȸ ÇѸ²´ëÇб³½ÅÀ忬±¸¼Ò ¿¬¼ö°ÁÂ
¸¸¼ºÄáÆÏº´ ¹× Åõ¼® ȯÀÚÀÇ ÁÖ¿ä»ç¸Á ¿øÀÎ, ¿¹¹æ, Áø´Ü, Ä¡·á
¾È³çÇϽʴϱî
ÇѸ²´ëÇб³ ½ÅÀ忬±¸¼Ò ¿¬¼ö°Á¿¡ ¿©·¯ºÐÀ» ÃÊ´ëÇÕ´Ï´Ù.
ÀúÈñ ÇѸ²´ë½ÅÀ忬±¸¼Ò´Â ÇѸ²´ëÇб³ Àǰú´ëÇÐ ±âÃÊÀÇÇÐ ±³½Ç°ú ÀÇ·á¿ø »êÇÏ 6°³ º´¿øÀÇ ½ÅÀå³»°ú ±³¼öµéÀ» Áß½ÉÀ¸·Î ¿ì¸®³ª¶óÀÇ ¸¸¼º ÄáÆÏº´¿¡ ´ëÇÑ ¿¬±¸ ¹× ÀÓ»ó Áø·áÀÇ ¹ßÀü¿¡ À̹ÙÁöÇϰíÀÚ 2003³â ù°ÉÀ½À» ½ÃÀÛÇÏ¿´À¸¸ç, ¾î´Àµ¡ °³¼Ò 16ÁÖ³âÀ» ¸ÂÀÌÇÏ°Ô µÇ¾ú½À´Ï´Ù.
±× µ¿¾È ÀúÈñ ½ÅÀ忬±¸¼Ò¿¡ º¸³»Áֽеû¶æÇÑ °ü½É°ú °Ý·Á¿¡ ±íÀÌ °¨»çµå¸³´Ï´Ù.
º» ¿¬±¸¼Ò¿¡¼´Â ¡°¸¸¼º ÄáÆÏº´ ȯÀÚ ¹× Åõ¼® ȯÀÚ¿¡¼ ÁÖ¿ä »ç¸Á¿øÀÎÀÇ ¿¹¹æ, Áø´Ü, Ä¡·á¡±¿¡ °üÇÑ ÁÖÁ¦·Î ¿¬¼ö°Á¸¦ °³ÃÖÇØ ¿Ô½À´Ï´Ù. À̹ø ¿¬¼ö°Á¿¡´Â ȯÀÚ¸¦ Áø·áÇÏ¸é¼ ÈçÈ÷ Á¢ÇÏ°Ô µÇ´Â Áõ»ó°ú °ü·ÃÇÏ¿© °í¹ÎµÇ´Â ¹®Á¦µé¿¡ ´ëÇÏ¿© ÀüÇØµå¸± ¿¹Á¤ÀÔ´Ï´Ù.
ÈĹݺο¡¼´Â Åõ¼® ȯÀÚÀÇ »ç¸Á·üÀ» ³·Ãߴµ¥ ÁÖ¿äÇÑ 3°¡Áö ¿¬Á¦¿Í ÇÔ²² ÀÇ·á±â°ü ÀÎÁõ Æò°¡ Áغñ, ƯÈ÷ Àΰø½ÅÀå½Ç ºÎ¹®¿¡ ´ëÇÑ 1°¡Áö ¿¬Á¦¸¦ ÁغñÇÏ¿´½À´Ï´Ù. ½Ç¹«ÀûÀÎ Áö½Äµé°ú Çö¾ÈµéÀ» Á¶¸íÇϰí ÀÓ»ó¿¡¼ Åõ¼® ȯÀÚ Áø·á¸¦ ½ÃÇàÇÏ´Â ¼±»ý´Ôµé°ú ±¸Ã¼ÀûÀ¸·Î ¼·ÎÀÇ °æÇèÀ» ³ª´©°í ÇÔ²² Åä·ÐÇÒ¼ö ÀÖ´Â ÀÚ¸®¸¦ ¸¶·ÃÇϰíÀÚ ÇÏ¿´½À´Ï´Ù.
¾Æ¹«ÂÉ·Ï ¸¸¼º ÄáÆÏº´ ¹× Åõ¼® ȯÀÚÀÇ Áø·á¸¦ ´ã´çÇÏ°í °è½Å ¿©·¯ ¼±»ý´Ôµé²² À̹ø ¿¬¼ö°Á°¡ Áø·áÀÇ ÇöÀå¿¡¼ ȯÀÚ¸¦ µ¹º¸½Ç ¶§ ¸¹Àº µµ¿òÀÌ µÇ´Â ÀÚ¸®°¡ µÇ½Ã±â¸¦ ±â¿øÇÏ¿À¸ç, ¹Ù»Ú½Ã´õ¶óµµ ºÎµð Âü¼®Çϼż ¾ËÂù ¸ðÀÓÀÌ µÉ ¼ö ÀÖµµ·Ï ¼º¿ø ºÎʵ右´Ï´Ù.
2018³â 9¿ù
ÇѸ²´ëÇб³ ½ÅÀ忬±¸¼Ò ¼ÒÀå ±èÇüÁ÷
ÇѸ²´ëÇб³ ½ÅÀå³»°ú ºÐ°úÀå À±Á¾¿ì
±¸ºÐ | Àü¹®ÀÇ/ÀüÀÓÀÇ | Àü°øÀÇ/°£È£»ç |
---|---|---|
»çÀüµî·Ï | 2¸¸¿ø | 1¸¸¿ø |
ÇöÀåµî·Ï | 3¸¸¿ø | 2¸¸¿ø |
½Ã°£ | Á¦¸ñ | °»ç |
---|---|---|
9:00 - 9:10 | Greeting | |
Session 1 | ÁÂÀå- ±èÇüÁ÷/³ëÁ¤¿ì | |
09:10 - 09:35 | Approach to the HD patient with unexplained eosinophilia or thrombocytopenia | ÇѸ²´ëÇб³ ÇѰ¼º½É ½ÅÀå³»°ú ±èµµÇü ±³¼ö |
09:35 - 10:00 | Osteoporosis in HD patients: a new insight into an old problem. | ÇѸ²´ëÇб³¼º½Éº´¿ø ½ÅÀå³»°ú ±èÁÂ°æ ±³¼ö |
10:00 - 10:25 | NOAC vs. Warfarin in HD patients | ÇѸ²´ëÇб³ °³²¼º½Éº´¿ø ½ÅÀå³»°ú ¹ÚÇýÀÎ ±³¼ö |
10:25 - 10:30 | Disscusion | |
10:30 - 10:50 | Break | |
Session 2 | ÁÂÀå- ±è¼º±Õ/ÀÌ¿µ±â | |
10:50 - 11:15 | Management of patients with a failed kidney transplant: Dialysis reinitiation, immunosuppression weaning, and transplantectomy | ÇѸ²´ëÇб³ µ¿Åº¼º½Éº´¿ø ½ÅÀå³»°ú ¹é¼±Çϱ³¼ö |
11:15 - 11:40 | HCV management in HD patients, an update of KDIGO HCV guideline | ÇѸ²´ëÇб³¼º½Éº´¿ø ½ÅÀå³»°ú ¼Û¿µ¸² ±³¼ö |
17:20 - 18:00 | Ȱµ¿¼º Æó°áÇÙ Á¢ÃËÀÚ °ü¸® ¹× Àẹ°áÇÙÀÇ Ä¡·á | ÇѸ²´ë¼º½Éº´¿ø °¨¿°³»°ú Á¤¿µÈñ |
Session 3 | ÁÂÀå- ±¸ÀÚ·æ/À±Á¾¿ì | |
11:40 - 12:05 | Common errors and mistakes in the ultrasound diagnostics of vascular access | ÇѸ²´ëÇб³¼º½Éº´¿ø ½ÅÀå³»°ú ÀÌÇü¼® ±³¼ö |
12:05 - 12:35 | Infection of vascular access: from early detection to treatment | ÇѸ²´ëÇб³¼º½Éº´¿ø ½ÅÀå³»°ú ÃÖ¼±·É ±³¼ö |
12:35 - 12:45 | Disscusion | |
12:45 - 12:55 | Wrapup&Closing |